News | October 12, 2025
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Several technologies for hemoglobinopathies are being transferred to commercial partners
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Subscribe To Our Newsletter & Stay Updated
